Skip to main content
Premium Trial:

Request an Annual Quote

FDA Licenses GVK's GOSTAR Database for Drug Repurposing Research

Premium

This week, GVK Biosciences said that the US Food and Drug Administration has licensed GOSTAR, a manually curated database of structure-activity relationship, pharmacokinetic, and toxicity data.

GOSTAR contains over 6.5 million manually curated compounds from over 2.5 million patents and 400,000 journals; and more than 18 million quantitative SAR points. It also includes a proprietary drug repurposing platform that pulls in data from other GVK Bio proprietary databases.

GVK Bio said that it will collaborate with the FDA on drug repositioning projects, the first of which will identify alternative therapeutic indications for compounds used to treat neglected and orphan diseases.

The firm will also work with the FDA to enhance GOSTAR's "repositioning and repurposing workflow, and make it available to the entire research community," according to Sreeni Devidas, GVK Bio's vice president of business development.

The financial details of the agreement were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more